Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGN-101
- Development stage
- Unknown
- Lead developer
- SGN Nanopharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic, Topical
01
Overview
SGN-101 is an investigational 0.05% micellar nanoparticle (MNP) ophthalmic emulsion of cyclosporine A, developed by SGN Nanopharma for the treatment of chronic dry eye disease (keratoconjunctivitis sicca). Utilizing a proprietary nanotechnology platform, SGN-101 delivers cyclosporine in neutral to positively-charged nanoparticles (150-170 nm) designed to enhance penetration into deep ocular tissues and reduce surface irritation compared to traditional oil-based formulations like Restasis. In 2024, SGN Nanopharma entered a collaboration with Eyenovia to develop SGN-101 as a drug-device combination product using the Optejet microdosing dispenser, which employs Microdose Array Print (MAP) technology for precise, low-velocity delivery. Clinical data from a randomized controlled trial of 155 subjects demonstrated that SGN-101 was statistically superior to Restasis (cyclosporine 0.05%) in improving dry eye symptoms starting at week 4 of treatment.
- Other names
- MNP cyclosporinecyclosporine 0.05% MNP ophthalmic emulsionmicellar nanoparticle cyclosporine
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on SGN-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGN-101.